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Introduction
Mesenchymal stem cells (MSCs) were first described by 
Friedenstein et al. [1,2]. MSCs are heterogeneous cell populations, 
called multipotent adult cells or somatic stem cells [3,4], capable 
of differentiation in most cell types in order to maintain and 
repair the organism. They are resident in different organs and 
tissues such as adipose tissue [4,5], bone marrow, umbilical cord, 
amniotic membrane [2,4], kidneys, liver, spleen, lungs, pancreas, 
tendons, synovial membranes, placenta, amniotic fluid and 
dental pulp [4]. The International Society for Cellular Therapy 
proposed three minimal criteria for defining MSCs: 
a) Plastic adherence; 
b) Positive expression (greater than 95% of the cell 
population) for CD105, CD73 and CD90 markers and 
negative, (maximum 2% of the population) for CD45, CD34, 
CD14, CD11b, CD79a, CD19 and Human leukocyte antigen 
(HLA-DR) surface molecules, and 
c) Ability to differentiate into osteoblasts, adipocytes 
and chondroblasts under standard in vitro differentiating 
conditions [2,6]. 
Later, others researchers complemented this characterization 
with new markers: CD13, CD44, CD54, 106 and Stro-1 [4] 
and the presentation of fibroblast cellular morphology [3,4].
MSCs have a great potential to the tissue repairment and 
regeneration in reconstructive plastic surgery, preventing 
ischemic lesions in skin flaps [7-14] and in skin grafts [15,16]. 
MSCs are capable of reducing severe atrophy, retraction, fibrosis 
and ulceration skin signals, caused by radiotherapy [17,18]. 
Combined with the lipoinjection in face and body defects and in 
rejuvenating esthetic treatments, MSCs raise in 35% the survival 
rate and the microvasculature from the injected fat [18]. Also, 
diabetic patients with ischemic wounds show greater survival 
rates and lower number of amputations in affected limbs, when 
treated with Adipose derived stem cells (ADSCs) [19]. The MSCs 
improved the skin healing at induced burns in rats [20,21]. In 
dermatology, the MSCs are being clinically used for inflammatory 
diseases [22-28], Graft-Versus-Host Disease [23,25], Chrown 
Disease [29], Systemic Sclerosis, Lupus or dermatomyositis 
[24,28,30].
When compared with the usage of Growing Factors, that like 
any drug has a limited half-life, the cellular therapy using MSCs, 
specially in its two subtypes - the Bone-Marrow Mesenchymal 
Stem Cells (BM-MSCs) and ADSCs - can bring greater benefits 
because of: their expansion capacity in cellular culture; stable 
phenotypic expression; and possibility of differentiating in 
specialized cells, that secrete and suppress cytokines and growing 
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factors in the injury [13,31-33]. However, long expansion periods 
of the cellular culture, to achieve effective therapeutic doses, 
raise the possibility of infection from the host. Because of that, 
the ADSCs still have to be heavily studied to the application in 
the clinic routine [2]. This way, this study has as objective briefly 
review the literature about the usage of MSCs and its subtypes, 
the ADSCs, to improve the skin healing.
Discussion
The MSCs are capable to answer and adjust their functions, 
when exposed to cells or typical factors of the lesion environment 
[33,34]. They have an attraction capacity to the inflammation 
areas [33-35] or tumors, because of the molecules CCL21 or 
HMGB1, known as homing. In case of lacking of this signalization, 
they are attracted in order of preference to the lungs, liver and 
spleen [35]. The MSCs show chemotaxis in vitro by the Stromal 
Cell-Derived Factor (SDF1), Platelet-Derived Growth Factor 
(PDGF), Insulin-Like Growth Factor-1, Interleukin-8 (IL-8) and 
Tumor Necrosis Factor-α (TNFα). In murine models, the MSCs 
used in the systemic administration are capable of getting into 
the damaged tissues [14,34,36]. 
The MSCs act, in many levels, in the three healing phases: 
inflammatory, proliferative and remodeling phase. Current 
studies indicate that the differentiation of the MSCs, that 
contributed to the tissue regeneration, is limited by the small 
survival rate of these cells in the damaged area. However, 
the paracrine signaling to the cells from the injury is the 
main mechanism of the MSCs, reducing the inflammation, 
stimulating the angiogenesis and inducing the cell migration and 
proliferation [33,37]. Nevertheless, other authors suggest that 
the differentiation of the MSCs in keratinocytes and endothelial 
cells have the same function as the paracrine signaling to 
accelerate the neovascularization and the reepithelialization of 
wounds [32] (Figure 1 & 2).
Figure 1: Full-thickness skin graft in rats: 
(A) Graft that received the application of 1 X 106 ADSCs in their subcutaneous tissue: (d5) appearance five days after surgery and (d14) 
aspect 14 days after surgery; 
(B) Graft that did not receive the application of ADSCs in its subcutaneous tissue: (d5) appearance with five postoperative days and (d14) 
aspect with 14 postoperative days, before removing the necrosis crust from the epidermis and after removing the crust.
Figure 2: Burn wounds by cold (liquid nitrogen) in rats: 
(C1d45) appearance of untreated wound 45 days after surgery; (S1d45) Wound treated with the intradermal application of NaCl 0.9% with 
45 postoperative days; (T1d45); Wound treated with 1 X 106 ADSCs in intradermal application with 45 postoperative days.
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Some studies suggest that immunosuppressive potential 
is the same of both types of MSCs, ADSCs and BM-MSCs, in an 
inflammatory environment. Their local administration inhibited 
the T cells recruitment and proliferation [37-41] and decrease 
Interferon-γ (IFNγ),Tumor Necrosis Factor-α (TNFα), IL-6 and 
IL-1β expression in the skin grafts [39-41]. In the inflammatory 
phase (one to three days), the expression of anti-inflammatory 
cytokines IL-4 and IL-10 is increased while IL-2 pro-
inflammatory cytokines, TNF-α and IFN-γ are decreased, causing 
less local inflammatory reaction [37,42]. MSCs can also regulate 
macrophage activation and convert phenotype expression of M1 
macrophages to M2 anti-inflammatory macrophages [39-41], 
which accelerates the wound healing. Additionally, MSCs act over 
the innate immunity to prevent the rejection of transplanted 
allografts, inhibiting the complement system activation [39]. The 
decrease of TFN-α also helps the reepithelialization after the 
proliferation phase [43]. The antimicrobial action from the MSCs 
are also important to limit the infection occurrence [37].
With the utilization of cell therapy in the proliferative 
phase (14 days) the production of important growth factors is 
increased: Vascular Endothelial Growth Factor (VEGF), Basic 
Fibroblast Growth Factor (bFGF) [32,37,42,43], Epidermal 
Growth Factor (EGF), Keratinocyte Growth Factor (KGF), 
Hepatocyte Growth Factor (HGF), Platelet-Derived Growth 
Factor (PDGF) and Transforming Growth Factor-beta (TGF-β). 
Through their paracrine action, the MSCs raise the migration 
and proliferation of keratinocytes, endothelial and epithelial 
cells. The fibroblasts proliferation is also enhanced, as well as 
the blood vessels’ formation. This way, there is a better growing 
of a more vigorous granulation tissue [33,37,42,43]. The 
angiogenesis is a very important factor to the wound’s healing, 
and the VEGF and the Fibroblast Growth Factor (FGF) are very 
important angiogenic factors [32].
Through the paracrine signaling, from the MSCs in the 
remodeling phase (21 days to one year), the fibroblasts produce 
collagen fibers in greater quantity and density, generating an 
increase in wound tensile strength [37,42,43]. At the same 
time, there is a smaller wound contraction and increased 
matrix-metalloproteinases production, that control the collagen 
deposition exacerbation, improving the aesthetic result and 
keeping the skin’s function [33,42,43]. MSCs also contribute to 
the scar’s appropriate remodeling with the increased secretion 
of VEGF and HGF, the adequate balance between TGF-β1 and 
TGF-β3 [37] and the increase of bFGF and TGF-β which inhibit 
the Alpha-Smooth Muscle Actin (α-SMA) expression, responsible 
for myofibroblast phenotype [32].
Studies indicate that there is also the possibility of using 
BM-MSCs and ADSCs to protect the damaged tissues caused 
by the Ischemia-Reperfusion Injury (IRI) and to decrease the 
dysfunction of organs undergoing ischemia. The ADSCs are able 
to protect axial flaps from the IRI with results as satisfactory 
as the ones obtained in procedures without ischemia, because 
of the improvement in the angiogenic response and the blood 
perfusion elevation [10]. Many studies use the ADSCs to prevent 
ischemic injuries in skin flaps [7-14], as others [15,16] used 
them to improve the quality of skin grafts.
Conclusion 
The MSCs - both BM-MSCs and ADSCs - are capable to answer 
and module their functions, when exposed to cells or typical 
factors of the lesion environment, attracted by the cell signaling 
to the inflammation areas. The researches developed till the 
moment point the paracrine signaling as the main mechanism 
from the MSCs, decreasing the inflammation, benefiting the 
angiogenesis and inducing the cell migration and proliferation 
in the damaged area. The progress on the researches about 
the association of MSCs with reconstructive surgery practices 
indicates good and productive results, which can benefit the 
clinical practice in this field.
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